SAN FRANCISCO and GENEVA, Oct. 16, 2014 (GLOBE NEW
Post# of 30028
Posted On: 10/17/2014 7:06:18 AM
SAN FRANCISCO and GENEVA, Oct. 16, 2014 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (AMBS), a biotechnology company focused on the development of diagnostics and therapeutics for Alzheimer's disease, Parkinson's disease and ophthalmological disorders, announced that it has applied to the US Food & Drug Administration for Orphan Drug Designation for MANF (mesencephalic-astrocyte-derived neurotrophic factor) in retinitis pigmentosa (RP). MANF was discovered utilizing Amarantus' proprietary PhenoGuard Protein Discovery Engine; all intellectual property is owned by the company.
Interesting that they "pumped " PhenoGuard in the opening statement in yesterday's PR.
I think that we will be hearing more about PhenoGuard shortly-could be a sleeping giant.
$AMBS$
Interesting that they "pumped " PhenoGuard in the opening statement in yesterday's PR.
I think that we will be hearing more about PhenoGuard shortly-could be a sleeping giant.
$AMBS$
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼